SCHEMBL5886243

SCHEMBL5886243

CCc1cc(N2CCOCC2)nnc1Cn1ccnc1-c1cccc(F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 3/20 0.40
▸ PIK3CD O00329 2/20 0.40
▸ PIK3CB P42338 2/20 0.40
▸ RAB9A P51151 1/20 0.39
▸ DGAT1 O75907 1/20 0.39
▸ SOAT1 P35610 1/20 0.39
▸ KDM4E B2RXH2 3/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ GRIA1 P42261 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PRKDC P78527 2/20 0.37
▸ GRIN2B Q13224 1/20 0.37
▸ PIK3CG P48736 1/20 0.37
▸ MC1R Q01726 1/20 0.37
▸ ATR Q13535 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886334 0.91 MAPT (0.39) RAB9AKDM4EALDH1A1MAPTMEN1
SCHEMBL5886435 0.87 ALDH1A1 (0.38) RAB9AKDM4EHSD17B10ALDH1A1MAPT
SCHEMBL4171889 0.80 ALDH1A1 (0.40) KDM4EHSD17B10ALDH1A1MAPTMEN1
SCHEMBL5886305 0.79 ALDH1A1 (0.39) KDM4EHSD17B10ALDH1A1MAPTMEN1
SCHEMBL5886351 0.79 ALDH1A1 (0.39) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL5886317 0.78 BRD4 (0.40) KDM4EHSD17B10ALDH1A1MAPTMEN1
SCHEMBL4166221 0.78 ALDH1A1 (0.38) KDM4EHSD17B10ALDH1A1MAPTMEN1
SCHEMBL5886328 0.76 ALDH1A1 (0.37) KDM4EHSD17B10ALDH1A1MAPTMEN1
SCHEMBL5886376 0.75 CYP1A1 (0.37) GAAALDH1A1MAPTMEN1KMT2A
SCHEMBL5886275 0.73 ALDH1A1 (0.35) KDM4EHSD17B10ALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7122546-B2 Imidazol-1-ylmethyl pyridazine derivatives NEUROGEN CORPORATION (US) 2006-10-17 — — US claimed
US-20040077653-A1 Imidazol-1-ylmethyl pyridazine derivatives NEUROGEN CORPORATION 2004-04-22 — — US claimed
US-7122546-B2 Imidazol-1-ylmethyl pyridazine derivatives NEUROGEN CORPORATION (US) 2006-10-17 — — US disclosed
WO-2004031174-A1 IMIDAZOL-1-YLMETHYL PYRIDAZINE DERIVATIVES NEUROGEN CORPORATION (US) 2004-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077653-A1 Imidazol-1-ylmethyl pyridazine derivatives GABRA5, GABRA1, GABRA2 PIK3CA 3360/4885PIK3CD 2046/4885PIK3CB 2057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback